# A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

> **NCT06675175** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 29 (actual)

## Conditions studied

- Chronic Kidney Disease
- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** AZD4144
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06675175
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-09
- **Primary completion:** 2025-10-27
- **Final completion:** 2025-10-27
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06675175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06675175, "A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06675175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*